Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma

• Published in: Chung-hua fu chʿan kʿo tsa chih Vol. 41; no. 2; p. 91
• Main Authors: Xi, Xiao-wei, Wan, Xiao-ping, Li, Shuang-di, Sun, Ting-wei, Zhu, Ya-ping
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2006
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CA-125 Antigen - blood; Chemotherapy, Adjuvant; Cisplatin - administration & dosage; Female; Half-Life; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms - blood; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Prognosis; Retrospective Studies; Survival Rate; Time Factors
• ISSN: 0529-567X

To investigate the relationship between the serum half life of CA(125) and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma treated with neoadjuvant chemotherapy. Clinical data of 39 patients who had undergone neoadjuvant chemotherapy were analyzed retrospectively. Patients were divided into two groups according to the serum half-life of CA(125), and the optimal operation rate and prognosis were compared. The optimal operation rate in patients with serum half-life >or= 20 days was significantly lower than that in patients with serum half-life < 20 days (29% vs 80%, P < 0.01). Cumulative survival was higher in patients with serum half-life < 20 days (P < 0.01). Serum half-life of CA(125) and tumor residual after operation were independent prognostic factors by COX model analysis. Serum half-life of CA(125) may indicate optimal debulking operation, and it is an independent prognostic factor in ovarian carcinoma patients treated with neoadjuvant chemotherapy.